117 related articles for article (PubMed ID: 38851463)
1. Impact of continuous-infusion meropenem degradation and infusion bag changes on bacterial killing of Pseudomonas aeruginosa based on model-informed translation.
Minichmayr IK; Friberg LE
Int J Antimicrob Agents; 2024 Jun; ():107236. PubMed ID: 38851463
[TBL] [Abstract][Full Text] [Related]
2. Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against
Minichmayr IK; Kappetein S; Brill MJE; Friberg LE
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009905
[TBL] [Abstract][Full Text] [Related]
3. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
5. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
6. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
7. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
8. Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating
Zhang X; Wang Y; Li S; Xie F; Yi H
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0154123. PubMed ID: 38319075
[TBL] [Abstract][Full Text] [Related]
9. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
10. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.
Cies JJ; Moore WS; Enache A; Chopra A
J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823
[TBL] [Abstract][Full Text] [Related]
12. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.
Hanberg P; Öbrink-Hansen K; Thorsted A; Bue M; Tøttrup M; Friberg LE; Hardlei TF; Søballe K; Gjedsted J
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530848
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria.
Kothekar AT; Divatia JV; Myatra SN; Patil A; Nookala Krishnamurthy M; Maheshwarappa HM; Siddiqui SS; Gurjar M; Biswas S; Gota V
Ann Intensive Care; 2020 Jan; 10(1):4. PubMed ID: 31925610
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.
Truong AQ; Dao XC; Vu DH; Nguyen HA; Do THG; Tran NT; Tran NM; Vu NB; Pham HN; Bui VC; Trinh TA; Dang QT; Nguyen GB; Lipman J; Cotta MO; Roberts JA
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0032122. PubMed ID: 36197095
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
[TBL] [Abstract][Full Text] [Related]
20. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
